7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Bone Cysts, Aneurysmal D017824 2 associated lipids
Bone Diseases, Developmental D001848 2 associated lipids
Actinomycosis D000196 2 associated lipids
Fractures, Stress D015775 2 associated lipids
Osteosclerosis D010026 2 associated lipids
Carcinoma, Neuroendocrine D018278 2 associated lipids
Osteophyte D054850 2 associated lipids
Lymphocytosis D008218 2 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Pericardial Effusion D010490 2 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Szulc P et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. 2011 J. Clin. Endocrinol. Metab. pmid:21565793
Zhang M et al. EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. 2011 J. Bone Miner. Res. pmid:20939055
Gurban CV and Mederle O The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. 2011 Rom J Morphol Embryol pmid:22119834
Millard SM et al. Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. 2011 J. Bone Miner. Res. pmid:20939063
Tanaka H et al. Expression of RANKL/OPG during bone remodeling in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21771583
Meulman T et al. Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. 2011 J. Periodont. Res. pmid:21726226
Reinhard H et al. Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. 2011 Cardiovasc Diabetol pmid:21801376
Gordon IK and Camphausen K Research highlights. 2011 Biomark Med pmid:21861664
Sood SK et al. Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. 2011 World J Surg pmid:21748518
Jabbar S et al. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. 2011 J. Periodont. Res. pmid:20731767
Lossdörfer S et al. PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. 2011 Clin Oral Investig pmid:20697756
McGrath EE OPG/RANKL/RANK pathway as a therapeutic target in cancer. 2011 J Thorac Oncol pmid:21849854
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
Harada S and Takahashi N [Control of bone resorption by RANKL-RANK system]. 2011 Clin Calcium pmid:21814016
Nakamura M and Udagawa N [Osteoporosis and RANKL signal]. 2011 Clin Calcium pmid:21814019
Persson E and Lerner UH The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. 2011 J. Cell. Biochem. pmid:21815197
Üstündağ M et al. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. 2011 J. Int. Med. Res. pmid:21819709
Bellido M et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. 2011 Osteoarthr. Cartil. pmid:21820069
Christoforidis A et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. 2011 Haemophilia pmid:20825502
Sudrová M et al. Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women. 2011 Clin. Appl. Thromb. Hemost. pmid:20682598
Riancho JA and Delgado-Calle J [Osteoblast-osteoclast interaction mechanisms]. 2011 Reumatol Clin pmid:21924211
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. 2011 Bone pmid:21925296
Fan R et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. 2011 Chin. Med. J. pmid:21933620
Osorio A et al. Mineral-bone metabolism markers in young hemodialysis patients. 2011 Clin. Biochem. pmid:21933667
Nybo M et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. 2011 Basic Clin. Pharmacol. Toxicol. pmid:21726411
Fradet A et al. Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. 2011 Cancer Res. pmid:21734015
Campbell GM et al. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. 2011 Osteoporos Int pmid:20480144
Choi EM Honokiol isolated from Magnolia officinalis stimulates osteoblast function and inhibits the release of bone-resorbing mediators. 2011 Int. Immunopharmacol. pmid:21621646
Ueland T et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. 2011 J. Intern. Med. pmid:21623962
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Karadag-Saygi E et al. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. 2011 Gynecol. Endocrinol. pmid:21627558
Taylor R et al. Osteoclast formation and function in pigmented villonodular synovitis. 2011 J. Pathol. pmid:21706481
Conaway HH et al. Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. 2011 J. Biol. Chem. pmid:21715325
El-Shehaby A et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. 2011 J. Clin. Immunol. pmid:21691937
Nich C et al. Oestrogen deficiency modulates particle-induced osteolysis. 2011 Arthritis Res. Ther. pmid:21696618
Roshandel D et al. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. 2011 Calcif. Tissue Int. pmid:21964949
Davenport C et al. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. 2011 J. Hypertens. pmid:21970938
Miyamoto K et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. 2011 J. Exp. Med. pmid:22006978
Cianciolo G et al. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 2011 Nephrol. Dial. Transplant. pmid:20659908
Di Bartolo BA et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. 2011 Cardiovasc. Res. pmid:21447702
Ho TY et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. 2011 Bone pmid:21419242
Chasseraud M et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. 2011 Ther Apher Dial pmid:21426505
Duheron V et al. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21402940
Dimitrow PP et al. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. 2011 J. Heart Valve Dis. pmid:21404893
Marques EA et al. Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. 2011 Exp. Gerontol. pmid:21316442
Chin A et al. Effects of medicinal herb salvia miltiorrhiza on osteoblastic cells in vitro. 2011 J. Orthop. Res. pmid:21319217
Brown TT et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. 2011 Antivir. Ther. (Lond.) pmid:22024522
Mainini G et al. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. 2011 Clin Exp Obstet Gynecol pmid:22268274
Riksen EA et al. Human osteoblastic cells discriminate between 20-kDa amelogenin isoforms. 2011 Eur. J. Oral Sci. pmid:22243268
Yener S et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? 2011 J. Endocrinol. Invest. pmid:20530985
Aydin H et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. 2011 Minerva Endocrinol. pmid:21519319
Altinova AE et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. 2011 Scand. J. Clin. Lab. Invest. pmid:21486111
Mercatali L et al. Bone metastases detection by circulating biomarkers: OPG and RANK-L. 2011 Int. J. Oncol. pmid:21491082
Stein SH et al. Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. 2011 J. Periodont. Res. pmid:21463327
Liang QQ et al. The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. 2011 Bone pmid:21466864
Honda K Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. 2011 J Oral Sci pmid:21467819
Moldenhauer A et al. Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. 2011 Eur. J. Immunol. pmid:21469100
Dimitri P et al. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. 2011 Bone pmid:20932948
Yu H et al. Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. 2011 Angle Orthod pmid:20936961
Palaniswamy C et al. Association of warfarin use with valvular and vascular calcification: a review. 2011 Clin Cardiol pmid:21298649
Bostanci N et al. Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. 2011 J. Clin. Periodontol. pmid:21261673
Bai P et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. 2011 Respir. Res. pmid:22176920
Sun Z and Tee BC Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. 2011 Anat Rec (Hoboken) pmid:21157918
Cannon JG et al. Follicle-stimulating hormone promotes RANK expression on human monocytes. 2011 Cytokine pmid:21159522
Choe JY et al. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. 2011 J. Rheumatol. pmid:21159831
Mahoney DJ et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. 2011 Arthritis Rheum. pmid:21162099
Čolović M et al. FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. 2011 Int. J. Hematol. pmid:21207214
Hashiguchi D et al. Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. 2011 J Biomed Mater Res A pmid:21171155
Li JY et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21187391
Garcia VG et al. Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. 2011 J. Clin. Periodontol. pmid:22092666
Hen K et al. [Osteoprotegerin--a new atherosclerosis marker]. 2011 Pol. Merkur. Lekarski pmid:22097184
Tang Y et al. Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide. 2011 J Endod pmid:22099899
Kuczkowski J et al. Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. 2010 Nov-Dec Am J Otolaryngol pmid:20015790
Kuczkowski J et al. [Molecular control of bone resorption in chronic otitis media with cholesteatoma]. 2010 Jul-Aug Otolaryngol Pol pmid:20873097
Reyes-García R et al. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. 2010 Jan-Feb Menopause pmid:19574937
Mori K et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. 2010 Feb-Mar Angiology pmid:19147525
Schramm HM The role of the osteoimmune axis in the inflammation of the inner auditory ear and with regard to the putative anticarcinogenetic principle: part 2. 2010 Inflamm Allergy Drug Targets pmid:20402646
Bartold PM et al. Mechanisms and control of pathologic bone loss in periodontitis. 2010 Periodontol. 2000 pmid:20403105
Nannuru KC et al. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. 2010 Cancer Res. pmid:20406980
Sanchez-Niño MD et al. New paradigms in cell death in human diabetic nephropathy. 2010 Kidney Int. pmid:20703212
Kauther MD et al. Biochemical markers of particle induced osteolysis in C57BL/6 mice. 2010 Clin. Chem. Lab. Med. pmid:20704528
Le Heron L et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. 2010 J. Cyst. Fibros. pmid:20005786
Shead EF et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. 2010 J. Cyst. Fibros. pmid:20006563
Ostrowski MC A new role for OPG: putting RANKL in its place. 2010 J. Bone Miner. Res. pmid:20684024
Eagan TM et al. Body composition and plasma levels of inflammatory biomarkers in COPD. 2010 Eur. Respir. J. pmid:20413541
Mine Y et al. Impact of titanium ions on osteoblast-, osteoclast- and gingival epithelial-like cells. 2010 J Prosthodont Res pmid:19733525
Xu DR et al. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]. 2010 Zhongguo Shi Yan Xue Ye Xue Za Zhi pmid:20416172
Saito-Yabe M et al. PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver. 2010 J. Pharm. Pharmacol. pmid:20663032
Pantsulaia I et al. Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers. 2010 Osteoarthr. Cartil. pmid:20633673
Passeri G et al. Adhesion pattern and growth of primary human osteoblastic cells on five commercially available titanium surfaces. 2010 Clin Oral Implants Res pmid:20636730
Stankovic KM et al. Differences in gene expression between the otic capsule and other bones. 2010 Hear. Res. pmid:20146935
Krause U et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. 2010 Proc. Natl. Acad. Sci. U.S.A. pmid:20150512
Subramaniam M et al. TGFbeta inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts. 2010 Biochem. Biophys. Res. Commun. pmid:20059964
Corallini F et al. TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. 2010 Cell. Mol. Life Sci. pmid:20063037
Zhang YG et al. Effect of negative pressure on human bone marrow mesenchymal stem cells in vitro. 2010 Connect. Tissue Res. pmid:20067412
Norazlina M et al. Effects of vitamin E on receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in rats treated with nicotine. 2010 Med. J. Malaysia pmid:21265240
Zhang J et al. [Effect of zoledronic acid on the differentiation and osteoprotegerin production of osteoblasts in rabbit]. 2010 Zhonghua Kou Qiang Yi Xue Za Zhi pmid:21122371
Kenanidis EI et al. Serum levels of bone turnover markers following total joint arthroplasty. 2010 J Orthop Surg (Hong Kong) pmid:21187538
Wang X et al. [Association of serum follicle stimulating hormone with osteoprotegerin, leptin, TGF-β1, and TGF-β2 in women]. 2010 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:21200095
Masuki H et al. Immunolocalization of DMP1 and sclerostin in the epiphyseal trabecule and diaphyseal cortical bone of osteoprotegerin deficient mice. 2010 Biomed. Res. pmid:21079361

Table of Content